PDS Biotech's disclosures have been opaque and confusing — and maybe on purpose,...
Julius Thomas: “It's important for people to understand that there's not a statu...
The CDC may be about to undergo a paradigm shift with the anticipated appointmen...
Employers and employees could fall into opposing camps, with workers demanding t...
Have you ever received test results in your email and found yourself panic-Googl...
Confo Therapeutics’s technology stabilises the selected GPCRs in their disease-r...
Healthcare R&D teams are increasingly using AI for drug development. Learn more ...
The use of AI in clinical trials is improving pharmaceutical R&D, speeding up ti...
Developing a new drug is a monumental achievement — the reward of years of resea...
The sNDA was submitted based on data obtained from the Phase III NAPOLI 3 trial.
PEMRYDI RTU is the first and only ready-to-use presentation of pemetrexed for in...
The company hopes to work with stakeholders to improve access to biosimilars acr...
Eloxx reanalysed data from a Phase II trial that previously missed its efficacy ...
Cullgen received a $35m upfront payment and is eligible for several milestone-ba...
Lilly will work on the development, manufacture and commercialisation activities...
“It’s a setback in patient safety and surveillance,” one expert said, "and will ...
